Motion sickness is a vestibular syndrome caused by sensory mismatch during movement, leading to nausea, dizziness, pallor, and sometimes vomiting. Severity varies by individual susceptibility and motion environment.
Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone), an atypical antipsychotic for schizophrenia and manic or mixed episodes in bipolar I disorder. The drug will be available by the third quarter of 2026.
The FDA approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for prevention of motion-induced vomiting on December 30, 2025. The approval marks the first new pharmacologic treatment for motion sickness in over four decades.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07297862 |
Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients |
ENROLLING_BY_INVITATION | |
| NCT06892340 |
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation |
RECRUITING | NA |
| NCT06587386 |
The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function |
COMPLETED | PHASE4 |
| NCT06354309 |
Impact of Different Types of Virtual Reality Games on Motion Sickness and Ocular in Adults: A Pilot Study |
COMPLETED | NA |
| NCT06232785 |
Gynecologic Endoscopic Surgery of Female Motion Sickness Patients |
COMPLETED | PHASE4 |
| NCT06138613 |
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06128707 |
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study |
COMPLETED | |
| NCT06106256 |
Three-Axis Wearable Adaptive Vestibular Stimulator |
ACTIVE_NOT_RECRUITING | NA |
| NCT06056622 |
Motion Sickness Rehabilitation for Virtual Reality |
COMPLETED | NA |
| NCT05903924 |
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness |
COMPLETED | PHASE3 |
